Sienna Cancer Diagnostics Ltd. has entered into an exclusive worldwide licence agreement with the University of Adelaide to develop and commercialise a unique cancer probe, SubB2M ­ a potential game-changer for detecting cancer, which is complementary to SIEN-NETTM and the BARD1 autoantibody assay for ovarian and breast cancer. As part of the exclusive licence, Sienna will collaborate with the University of Adelaide and Griffith University's Institute for Glycomics to provide the data needed to commercialise cancer screening and diagnostic assays based on SubB2M. The first stage will focus on developing a high throughput ELISA-based liquid biopsy assay for cancer screening and monitoring suitable for use in hospital pathology laboratories. It is anticipated that this will take 12-18 months to complete. In parallel, Sienna will actively develop SubB2M for other applications, including a novel circulating tumor cell capture assay and a novel reagent for PET imaging in conjunction with industry partners. Appropriate industry partners for these applications have been identified and discussions are progressing well.